Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$11.21 USD

11.21
1,876,113

+0.04 (0.36%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $11.19 -0.02 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Dynavax Technologies Corporation [DVAX]

Reports for Purchase

Showing records 101 - 120 ( 121 total )

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 101

05/25/2011

Daily Note

Pages: 4

Data From First Phase III HEPLISAV Study Expected Within 8 Weeks

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 102

05/06/2011

Company Report

Pages: 6

Q1:2011 Financial Recap; Expect Phase III HEPLISAV Data in Mid-2011

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 103

03/24/2011

Company Report

Pages: 11

Assuming Coverage with OUTPERFORM and Lowering Fair Value to $6 from $9; Optimistic on HEPLISAV

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 104

02/28/2011

Company Report

Pages: 8

Pipeline Progress: Universal Flu Vaccine and Hepatitis B Therapeutic Vaccine

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 105

02/23/2011

Company Report

Pages: 5

Heplisav Passes 4th DSMB Safety Review; Raising PT to $9

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 106

02/14/2011

Industry Report

Pages: 5

Biotechnology / Biopharmaceuticals - Potential Q1:11 Movers

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 107

02/14/2011

Daily Note

Pages: 5

Potential Q1:11 Movers

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 108

12/17/2010

Daily Note

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 109

12/10/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 110

11/09/2010

Company Report

Pages: 9

Adding the Diabetes Opportunity: Raising PT to $8

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 111

10/04/2010

Daily Note

Pages: 130

2010 AASLD Preview from Full Abstracts.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 150.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 112

09/29/2010

Company Report

Pages: 9

Heplisav Passes 3rd DSMB Safety Review

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 113

08/24/2010

Industry Report

Pages: 22

2010 AASLD Abstract Titles Review - Second Wave Including Late-Breakers

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 75.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 114

08/04/2010

Industry Report

Pages: 15

Life Sciences -MAC Best Ideas Conference - Key Takeaways New York City.

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 115

08/02/2010

Company Report

Pages: 6

Q2 Earnings Non-Event; Awareness on the Rise as Phase III Data Release Draws Near.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 116

07/07/2010

Company Report

Pages: 9

Universal Flu Vaccine Enters Phase I

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 117

06/17/2010

Company Report

Pages: 25

Heplisav Studies on Track; Nature Publication Highlights Upside; Reiterate OP.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 75.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 118

05/17/2010

Industry Report

Pages: 17

Mid Year 2010 HCV Update.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU K

Price: 50.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 119

05/12/2010

Company Report

Pages: 26

Betting on Heplisav: Assuming Coverage, Upgrading to Relative OUTPERFORM and Increasing Price Target to $6

Provider: WEDBUSH SECURITIES INC.

Analyst: XU K

Price: 75.00

Research Provided by a Third Party

Company: Dynavax Technologies Corporation

Industry: Medical - Biomedical and Genetics

Record: 120

03/17/2010

Industry Report

Pages: 30

Summary of Poster Presentations and Update of DAA Cross Comparison Table

Provider: WEDBUSH SECURITIES INC.

Analyst: XU K

Price: 75.00

Research Provided by a Third Party